Skip to main content
Premium Trial:

Request an Annual Quote

Lewis Joins Illumina from BD, Shanahan Named to Life Technologies Board, Cellular Dynamics Bolsters Exec Team, and More

NEW YORK (GenomeWeb News) - Mark Lewis has been named senior VP of development at Illumina, a role in which he will be responsible for global product development efforts. Lewis came to Illumina from Becton Dickinson Biosciences, where he was an executive involved in business development, and he recently was VP of special order research products. He also was involved in genomics technology research, gene characterization and discovery, and disease profiling at Aeomecia, and he led genotyping and DNA sequencing research at Molecular Dynamics.

Life Technologies has tapped William Shanahan to join its board of directors. Shanahan is the former president of Colgate-Palmolive, a post he kept from 1992 to 2005, and he is currently on the board of directors at Visa and MSD Ignition.

23andMe has hired Sarah Imbach to take over the role of chief operating officer and Larry Tesler to be a product fellow. Imbach formerly was VP of revenue and customer operations, and she previously was a senior VP of customer service operations and fraud at PayPal.
Tesler has been VP of user experience and design and a research fellow at Yahoo, and he formerly was VP of shopping experience at

Cellular Dynamics International has added three new faces to its executive team, naming Chris Kendrick-Parker as chief commercial officer; Emile Nuwaysir as chief operating officer; and David Snyder as chief financial officer.
Kendrick-Parker formerly was VP of global pharmaceutical business at Affymetrix, and he was involved in drug discovery at Amersham Pharmacia. Nuwaysir was senior VP of program management and business development and he was CTO at Roche NimbleGen, and a manager at NimbleGen Systems prior to the company’s acquisition by Roche. He served as a researcher at the National Human Genome Research Institute and the National Institute of Environmental Health Sciences, where he helped to establish the National Center for Toxicogenomics. Snyder was site VP and CFO for Roche NimbleGen, and he helped lead NimbleGen through its initial public offering.

Richard Schifreen has taken over as president and CEO of Platypus Technologies. He has served as VP of research products at Mirus Bio and prior to that he was director of technology and business development at Promega. Schifreen also is a former faculty member at the University of Wisconsin School of Medicine and Public Health and a member of the cardiovascular medicine advisory board.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.